Sign In
Buy MYNZ
$0.700
+0 (+0%)
At Close: Jul 31, 2026
BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82% 690 subjects analyzed including p
Mainz Biomed Reports Full Year 2023 Financial Results
08:01am, Tuesday, 09'th Apr 2024
BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
08:01am, Tuesday, 19'th Mar 2024
BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
08:01am, Monday, 18'th Mar 2024
BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
08:01am, Tuesday, 12'th Mar 2024
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
01:01pm, Friday, 08'th Mar 2024
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration Mainz Biomed's Pivotal FDA PMA clinical
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
08:01am, Tuesday, 27'th Feb 2024
BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
08:01am, Thursday, 22'nd Feb 2024
BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
08:01am, Wednesday, 21'st Feb 2024
BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
08:01am, Tuesday, 06'th Feb 2024
BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
08:01am, Thursday, 11'th Jan 2024
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Provides Year-End Corporate Review 2023
08:01am, Tuesday, 09'th Jan 2024
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition ReconAAsense designed to eva
Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.
